Bcr-Abl inhibition as a modality of CML therapeutics

Elisabeth Buchdunger, Alex Matter, Brian J. Druker

Research output: Contribution to journalReview article

92 Scopus citations
Original languageEnglish (US)
Pages (from-to)M11-M18
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1551
Issue number1
DOIs
StatePublished - Aug 31 2001

Keywords

  • Bcr-Abl
  • Chronic myelogenous leukemia
  • STI571
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this